Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Treatments for sore throat linked to acute pharyngitis and viral tonsillitis

Official title: Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and/or Viral Tonsillitis

Run by University Hospital, Clermont-Ferrand · NCT07569939 · Data updated 2026-11-12

This post-marketing follow-up checks four products (HMG, PHN, PHR, TUR) in people with sore throats from acute pharyngitis or viral tonsillitis to see if they are safe and helpful in real-world use.

More Sore Throat trials

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment160 (estimated)
SponsorUniversity Hospital, Clermont-Ferrand
Academic / other
Locations1 site (Clermont-Ferrand)
StatusRecruiting
StartedJuly 29, 2026
Main results expectedJanuary 2028
Study endsJanuary 2028
Registry record updatedAugust 5, 2026
Trial IDNCT07569939 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults and eligible female patients of childbearing potential who have acute sore throat onset within 72 hours and are affiliated with the French Social Security system, able to consent and follow study procedures.

Probably not a fit

Patients with severe complications, confirmed influenza/COVID-19 requiring specific treatment, or those with hypersensitivity to any product components may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study collects real-world clinical data to monitor the tolerance, safety, and efficacy of four medical devices used for sore throat related to acute pharyngitis and viral-origin tonsillitis. It is an observational, post-marketing follow-up rather than a randomized trial. Participants must have sore throat with onset within 72 hours and meet specific inclusion criteria, while excluding those with certain infections or allergies. Data are gathered in routine clinical settings to assess risk/benefit in typical use. The lead sponsor is University Hospital, Clermont-Ferrand, with participation at Chu Clermont Ferrand in Clermont-Ferrand, France.

Why it matters

Potential benefit: If successful, the study could confirm that these devices are safe and helpful for patients with sore throats from viral or acute pharyngitis origins in real-world use.

How similar studies have gone: Previous post-marketing follow-ups have shown variable safety and performance for similar devices in real-world sore throat management; this study aims to corroborate their tolerability and efficacy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment
* Bacterial rhinopharyngitis with negative TROD test
* Effective contraception for female patients of childbearing age
* Cooperation and sufficient understanding to comply with the requirements of the trial
* Acceptance of registration in the SI-RIPH database
* Having received informed information and agreeing to give written consent
* Affiliated with the French Social Security scheme.

Exclusion Criteria:

* Hypersensitivity/previous allergy to any of the product components,
* Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough,
* Positive antigen test for influenza A/B or COVID-19 and infection requiring etiological treatment according to the recommendations,
* Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…),
* Comorbidities or health conditions deemed incompatible with the trial by the investigator,
* Recent otorhinolaryngology surgery (\<6 months),
* Pulmonary pathology (Chronic Obstructive Pulmonary Disease, asthma…),
* Immunosuppression (according to patient's report),
* Pregnant or breastfeeding women,
* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,
* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).

Where it's running

  • Chu Clermont Ferrand
    Clermont-Ferrand, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.